End-to-End Discovery Icagen offers Target-to-Lead (T2L) partnerships and multi-year, integrated drug discovery programs, enabling pharma and biotech clients to outsource early discovery and fill R&D gaps with a partner that brings over two decades of North American experience.

Target Expertise With deep target-based discovery capabilities across ion channels, kinases, GPCRs and transporters, Icagen can perform target feasibility assessments using computational chemistry and rapid prioritization to help clients de-risk early programs and accelerate lead identification.

North American Presence Based in Durham, North Carolina, Icagen’s US presence supports close collaboration with regional pharma and biotech partners, potentially enabling faster start-ups, easier regulatory alignment, and co-development opportunities.

Tech-Driven Capabilities Leveraging AWS, uHTS, virtual screening and analytics, Icagen can scale screening and lead discovery for clients needing high-throughput capabilities and data-backed decision making.

Flexible Partnerships Flexible engagement models—from piecemeal projects to long-term discovery partnerships—allow firms to start with targeted work and expand into full lead optimization services, creating cross-sell opportunities in medicinal chemistry, biology, and translational research.